INVO Bioscience (INVO) Competitors $1.46 +0.04 (+2.82%) As of 06/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock INVO vs. FEMY, GBS, ALUR, RVP, PETV, ADGM, NXGL, XAIR, MHUA, and VVOSShould you be buying INVO Bioscience stock or one of its competitors? The main competitors of INVO Bioscience include Femasys (FEMY), GBS (GBS), Allurion Technologies (ALUR), Retractable Technologies (RVP), PetVivo (PETV), Adagio Medical (ADGM), NEXGEL (NXGL), Beyond Air (XAIR), Meihua International Medical Technologies (MHUA), and Vivos Therapeutics (VVOS). These companies are all part of the "surgical & medical instruments" industry. INVO Bioscience vs. Its Competitors Femasys GBS Allurion Technologies Retractable Technologies PetVivo Adagio Medical NEXGEL Beyond Air Meihua International Medical Technologies Vivos Therapeutics Femasys (NASDAQ:FEMY) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends. Do institutionals & insiders have more ownership in FEMY or INVO? 65.3% of Femasys shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 11.5% of Femasys shares are owned by company insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, FEMY or INVO? Femasys has a beta of -2.62, suggesting that its share price is 362% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Do analysts recommend FEMY or INVO? Femasys presently has a consensus target price of $8.67, suggesting a potential upside of 836.94%. Given Femasys' stronger consensus rating and higher probable upside, research analysts clearly believe Femasys is more favorable than INVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00INVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to FEMY or INVO? In the previous week, Femasys had 5 more articles in the media than INVO Bioscience. MarketBeat recorded 5 mentions for Femasys and 0 mentions for INVO Bioscience. Femasys' average media sentiment score of 0.68 beat INVO Bioscience's score of 0.00 indicating that Femasys is being referred to more favorably in the media. Company Overall Sentiment Femasys Positive INVO Bioscience Neutral Is FEMY or INVO more profitable? INVO Bioscience has a net margin of -122.79% compared to Femasys' net margin of -1,435.77%. INVO Bioscience's return on equity of 0.00% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,435.77% -141.49% -82.30% INVO Bioscience -122.79%N/A -36.94% Which has stronger earnings & valuation, FEMY or INVO? INVO Bioscience has higher revenue and earnings than Femasys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.70M13.91-$14.25M-$0.91-1.02INVO Bioscience$5.77M0.96-$8.03MN/AN/A Does the MarketBeat Community believe in FEMY or INVO? Femasys received 32 more outperform votes than INVO Bioscience when rated by MarketBeat users. Likewise, 73.58% of users gave Femasys an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote. CompanyUnderperformOutperformFemasysOutperform Votes3973.58% Underperform Votes1426.42% INVO BioscienceOutperform Votes746.67% Underperform Votes853.33% SummaryFemasys beats INVO Bioscience on 10 of the 16 factors compared between the two stocks. Get INVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for INVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVO vs. The Competition Export to ExcelMetricINVO BioscienceSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.56M$4.37B$5.61B$8.62BDividend YieldN/A42.67%5.28%4.17%P/E RatioN/A28.2927.2119.96Price / Sales0.9670.02408.49157.63Price / CashN/A51.0838.2534.64Price / Book-0.715.827.074.69Net Income-$8.03M$67.63M$3.23B$248.14M7 Day Performance-2.01%-1.03%0.68%0.91%1 Month Performance-31.46%16.63%9.59%5.71%1 Year Performance54.12%18.79%32.02%14.71% INVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVOINVO BioscienceN/A$1.46+2.8%N/A+97.8%$5.56M$5.77M0.0025FEMYFemasys3.1073 of 5 stars$0.84+1.2%$8.67+931.7%-11.1%$22.88M$1.70M-1.0430News CoverageAnalyst ForecastGBSGBSN/A$1.41-5.4%N/A-11.6%$21.00M$440K-2.527ALURAllurion Technologies3.488 of 5 stars$2.67-1.8%$22.83+754.9%-92.6%$19.92M$28.30M-0.22501Positive NewsShort Interest ↓RVPRetractable Technologies1.2804 of 5 stars$0.66+1.5%N/A-39.6%$19.76M$33.75M-1.22240Gap DownPETVPetVivoN/A$0.76-0.2%N/A+9.5%$18.57M$1.05M-1.7020Gap DownADGMAdagio MedicalN/A$1.17+3.1%N/AN/A$17.92M$266K0.0087Positive NewsNXGLNEXGEL1.1102 of 5 stars$2.21+1.0%N/A-3.9%$16.93M$10.23M-3.8110XAIRBeyond Air4.4817 of 5 stars$0.18-2.0%$1.50+728.7%-85.3%$15.63M$3.02M-0.1770Upcoming EarningsGap DownMHUAMeihua International Medical Technologies1.7306 of 5 stars$0.57+7.4%N/A-50.0%$14.27M$96.91M0.00620Short Interest ↓VVOSVivos Therapeutics1.5867 of 5 stars$2.35-2.1%$4.82+105.0%-9.0%$13.84M$14.63M-0.41160Short Interest ↑Gap Down Related Companies and Tools Related Companies Femasys Competitors GBS Competitors Allurion Technologies Competitors Retractable Technologies Competitors PetVivo Competitors Adagio Medical Competitors NEXGEL Competitors Beyond Air Competitors Meihua International Medical Technologies Competitors Vivos Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVO) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INVO Stock Free INVO Stock Alerts